Evidence map›Paper›PMID 42078337›Full record

ArticlemedRxiv : the preprint server for health sciences2026

AI/ML-based prediction of TB treatment failure: A systematic review and meta-analysis.

Rogers Kamulegeya, Rose Nabatanzi, Derrick Semugenze, Faridah Mugala, Mercy Takuwa, Emmanuel Nasinghe, Denis Musinguzi, Sharon Namiiro, Andrew Katumba, Willy Ssengooba and 3 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Rogers KamulegeyaDepartment of Immunology and Molecular Biology, Makerere University College of Health Sciences (MakCHS), Kampala, Uganda.
Rose NabatanziDepartment of Immunology and Molecular Biology, Makerere University College of Health Sciences (MakCHS), Kampala, Uganda.
Derrick SemugenzeDepartment of Immunology and Molecular Biology, Makerere University College of Health Sciences (MakCHS), Kampala, Uganda.
Faridah MugalaDepartment of Immunology and Molecular Biology, Makerere University College of Health Sciences (MakCHS), Kampala, Uganda.
Mercy TakuwaDepartment of Immunology and Molecular Biology, Makerere University College of Health Sciences (MakCHS), Kampala, Uganda.
Emmanuel NasingheDepartment of Immunology and Molecular Biology, Makerere University College of Health Sciences (MakCHS), Kampala, Uganda.
Denis MusinguziDepartment of Computer Science, College of Computing and Information Sciences, Makerere University (CoCIS), Kampala, Uganda.
Sharon NamiiroMasaka Regional Referral Hospital, Masaka, Uganda.
Andrew KatumbaDepartment of Electrical and Computer Engineering, College of Engineering, Art and Design, Makerere University (CEDAT), Kampala, Uganda.
Willy SsengoobaDepartment of Immunology and Molecular Biology, Makerere University College of Health Sciences (MakCHS), Kampala, Uganda.ORCID 0000-0002-1643-110X
Joyce Nakatumba-NabendeDepartment of Computer Science, College of Computing and Information Sciences, Makerere University (CoCIS), Kampala, Uganda.
Florence Nameere KivunikeDepartment of Information Technology, College of Computing and Information Sciences, Makerere University (CoCIS), Kampala, Uganda.
David Patrick KateeteDepartment of Immunology and Molecular Biology, Makerere University College of Health Sciences (MakCHS), Kampala, Uganda.ORCID 0000-0001-8075-3069

Funding

Makerere University Data Science Research Training to Strengthen Evidence-Based Health Innovation, Intervention and Policy (MakDARTA)U2RTW012116 · FIC · MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES · PI William Checkley, Moses Lutaakome Joloba · 2021 to 2026
$2.0M
Tuberculosis in households with infectious cases in Kampala city: Harnessing health data science for new insights on TB transmission and treatment response (DS-IAFRICA-TB)U01TW012534 · FIC · MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES · PI KATEETE, DAVID PATRICK, NAKATUMBA, JOYCE NABENDE · 2023 to 2025
$750k
FIC NIH HHS U01 TW012534FIC NIH HHS U2R TW012116
6 · The paper itself

Abstract

Background: Tuberculosis (TB) remains a leading cause of infectious disease mortality worldwide, and treatment failure contributes to ongoing transmission, drug resistance, and poor clinical outcomes. Artificial intelligence and machine learning approaches have attracted growing interest for predicting tuberculosis treatment outcomes, but the literature is heterogeneous and lacks a comprehensive synthesis. Methods: We conducted a systematic review and meta-analysis of studies that developed or validated machine learning models to predict TB treatment failure. We searched PubMed/MEDLINE and Embase from January 2000 to October 2025. Studies were eligible if they developed, validated, or implemented an artificial intelligence or machine learning model for the prediction of TB treatment failure or a closely related poor outcome in patients receiving anti-TB treatment. Risk of bias was assessed using the Prediction model Risk Of Bias Assessment Tool. Random-effects meta-analysis was performed to pool area under the curve values, with subgroup analyses and meta-regression to explore heterogeneity. Results: Thirty-four studies were included in the systematic review, of which 19 reported area under the curve values suitable for meta-analysis (total participants, 100,790). Studies were published between 2014 and 2025, with 91% published from 2019 onward. Tree-based methods were the most common algorithm family (52.9%), and multimodal models integrating three or more data types were used in 41.2% of studies. The pooled area under the curve was 0.836 (95% confidence interval 0.799-0.868), with substantial heterogeneity (I Conclusions: Machine learning models for predicting TB treatment failure show promising discrimination but are not yet ready for routine clinical implementation. Performance varies substantially across populations and settings, and methodological limitations, including inadequate validation, poor calibration assessment, and high risk of bias, limit confidence in current estimates. Future research should prioritize rigorous external validation, calibration assessment, and development in underrepresented populations, particularly HIV-affected and high-burden settings.

Identifiers

PMID42078337
PMCPMC13131719

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.